<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525937</url>
  </required_header>
  <id_info>
    <org_study_id>Racial Disparities</org_study_id>
    <nct_id>NCT04525937</nct_id>
  </id_info>
  <brief_title>Racial and Economic Disparities and Unmet Needs in Patients With Severe Aortic Valvular Disease</brief_title>
  <official_title>Racial and Economic Disparities and Unmet Needs in Patients With Severe Aortic Valvular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Heart Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Heart Institute Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Common barriers to receiving appropriate guideline-driven care for patients with severe&#xD;
      aortic stenosis include referral biases by primary care providers (lack of provider&#xD;
      education), patient comorbidities (degree of fragility), as well as psychosocial issues and&#xD;
      cultural barriers. Additionally, race, ethnicity, socioeconomic status (SES) and education&#xD;
      level are shown to be persistent barriers to accessing healthcare services and healthcare&#xD;
      systems, creating a significant practice gap between various patient populations. The most&#xD;
      recent transcatheter valve therapies (TVT) registry data show that &gt;94% of TAVR recipients&#xD;
      are Caucasian, followed by less than 4% of African-Americans and Hispanics, respectively.&#xD;
      There is a critical need to understand the barriers to treatment and care among severe aortic&#xD;
      valve disease patients of disparate groups. This study is a multi-center, retrospective and&#xD;
      prospective cohort study of patients diagnosed with severe aortic stenosis. Additionally, we&#xD;
      will be surveying referring primary care providers, cardiologists and cardiovascular surgeons&#xD;
      to assess their current referral practices for patients with severe aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Mortality</measure>
    <time_frame>30 days and 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MACE (Major Adverse Cardiac Event)</measure>
    <time_frame>30 days and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Referring physician- related barriers/biases.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Secondary outcomes (Providers): referring physician-related barriers/biases against routine guideline-driven care for members of disparate groups with severe aortic stenosis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Disparities in Treatment of Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Patients with Severe Aortic Stenosis with Disparities</arm_group_label>
    <description>Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Providers with Disparities</arm_group_label>
    <description>Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Questionnaire</intervention_name>
    <description>Patient Questionnaire</description>
    <arm_group_label>Patients with Severe Aortic Stenosis with Disparities</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Provider Questionnaire</intervention_name>
    <description>Provider Questionnaire</description>
    <arm_group_label>Medical Providers with Disparities</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients:&#xD;
&#xD;
        - Over 18 years of age with echocardiographic diagnosis of severe, symptomatic AS and&#xD;
        intermediate to high surgical risk per Society of Thoracic Surgeons (STS) mortality&#xD;
        risk-score who have a disparate condition&#xD;
&#xD;
        Providers:&#xD;
&#xD;
        - Referring primary care providers, cardiologists and cardiovascular surgeons at the study&#xD;
        sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disparity/Diversity background (either race/ethnicity, low SES (adults with incomes at&#xD;
             or below the federal poverty level (family income to poverty ratio, ≤1), language&#xD;
             (non-English speaker) or education (≤9 years of education))&#xD;
&#xD;
          -  Patient scheduled for transcatheter aortic valve replacement using the Edwards Sapien&#xD;
             valve, OR recently implanted with Edwards Sapien valve (up to 1 year post-TAVR)&#xD;
&#xD;
          -  Echocardiographic diagnosis of severe, symptomatic AS and intermediate to high&#xD;
             surgical risk per Society of Thoracic Surgeons (STS) mortality risk-score&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Patients who do not allow their records to be used for research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Goessl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pam Morley, BSN</last_name>
    <phone>612-863-3833</phone>
    <email>pamela.morley@allina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn Witt, PhD</last_name>
    <phone>612-863-3833</phone>
    <email>dwitt@mhif.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Goessl, MD, PhD</last_name>
      <phone>612-863-3833</phone>
      <email>mario.goessl@allina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Disparities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

